Cobimetinib in advanced melanoma with BRAF V600 mutation: Added benefit now considerable

Posted by on June 3, 2016 3:03 pm
Categories: health

Further advantages of the drug Cobimetinib in comparison with the comparator therapy resulted from the analyses subsequently submitted by the drug manufacturer in the commenting procedure.

Leave a Reply

Your email address will not be published. Required fields are marked *